Detailed explanation of the key contents and medication precautions of the official instructions of Lebolayseng (Davico)

Lemborexant () is a new type of dual orexin receptor antagonist (DORA), mainly used to treat adult insomnia, especially patients who have difficulty falling asleep and are prone to waking up at night. The orexine system is an important neural pathway in the brain that regulates wake and sleep-wake cycles. Leborexan inhibits the overactivity of arousal signals by selectively antagonizing OX1R and OX2R receptors, thereby helping patients fall asleep quickly and extend their continuous sleep time, while reducing the number of nighttime awakenings. Compared with traditional benzodiazepine or non-benzodiazepine hypnotics, leborexan has the characteristics of low drug resistance, low dependence and less interference with cognitive function, which gives it unique advantages in modern insomnia treatment.

According to the official instructions, the recommended starting dose of leborexan is 5 mg orally once per night, before going to bed. Based on patient tolerance and clinical efficacy, the dose can be adjusted to 10mg. When taking the medicine, you should swallow the tablet whole and do not chew, crush or divide it. At the same time, you should ensure at least 7 hours of continuous sleep to ensure that the medicine is effective. Elderly patients or those with mild or moderate impairment of liver function should use it with caution, start with a lower dose and gradually adjust it under the guidance of a doctor. In addition, patients should maintain a regular schedule during use and try to go to bed at a fixed time to improve the treatment effect.

In clinical use, adverse reactions of leborexan are usually mild, with the most common ones including drowsiness, dizziness, abnormal dreams, and mild cognitive impairment. Most patients' symptoms will gradually lessen after continuing to take the medication for a period of time. It is worth noting that some patients may experience sleep-related behavioral abnormalities, such as sleepwalking, eating at night, or walking around at night. Once this occurs, the drug should be discontinued immediately and contact a doctor. Also, the drug may cause mild muscle weakness or ataxia, so high-risk activities such as driving or operating heavy machinery should be avoided during the initial period of use.

The drug metabolism of leborexan mainly depends on the liverCYP3A enzyme, so you need to pay attention to drug interactions when taking drugs together. Concomitant use with strong CYP3A inhibitors (such as ketoconazole, clarithromycin) may increase plasma concentrations and aggravate adverse reactions; concomitant use with strong CYP3A inducers (such as rifampicin, carbamazepine) may reduce the efficacy. In addition, patients should avoid excessive intake of alcohol or caffeinated beverages while taking the medication to reduce sleep disruption and medication side effects. Doctors usually adjust the dosage regularly based on the patient's medication history, sleep quality and adverse reactions to ensure the best balance between efficacy and safety.

In summary, leborexan, as a new generation of insomnia treatment drugs, provides a safe and effective treatment option for adult insomnia patients with its unique mechanism of action and low dependence. By following the medication guidance of the official label, reasonable adjustment of dosage and lifestyle management, patients can obtain significant benefits in improving the time it takes to fall asleep, prolong sleep duration and improve sleep quality, while minimizing potential risks. Its scientific medication strategy and continuous follow-up mechanism enable Lebraxen to demonstrate good clinical application value in the management of insomnia.

Reference link:https://www.drugs.com